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On the 7th of May 2002 a conference of the Cancer Research UK
Phase I/II Clinical Trials Committee was held to commemorate the
achievements of the late Professor Tom Connors in the field of
cancer drug development. Tom Connors died on the 4th of
February 2002 from the disease he had spent his life studying, and
obituaries chronicling his many scientific and personal attributes
and contributions have been written (Double, 2002; Newell, 2002).
Arguably Tom’s greatest achievement was the establishment of
the Cancer Research UK, formerly Cancer Research Campaign
(CRC), Phase I/II Committee with Laszlo Lajtha and Brian Fox in
1980. Hence, the Committee Tom had created and steered to
outstanding international recognition and scientific success
dedicated the first meeting after his death to reviewing the
laboratory and clinical research that Tom had undertaken and
made possible. The meeting was both a retrospective review and a
forward look at developmental therapeutics in all its forms: small
molecule, macromolecule, gene therapy and immunological.
Peppered throughout the presentations were not only references
to Tom’s scientific contributions, but also anecdotes and
reminiscences collected during 30 years of cancer research, these
brought both smiles and tears of laughter to the assembled
committee members, and to his widow, Pearl, and daughter, Clare,
who were there.
As Gordon McVie, the former Director General of the Cancer
Research Campaign, who strongly supported the Committee’s
activities, pointed out in his summary, there can be very few who
have contributed as much as Tom Connors to cancer research.
This article reflects those aspects of Tom’s work related to the
activities of the Cancer Research UK Phase I/II Clinical Trials
Committee.
TOM CONNORS AND THE CANCER RESEARCH CAMPAIGN,
NATIONAL CANCER INSTITUTE USA AND EUROPEAN
ORGANISATION FOR RESEARCH AND TREATMENT OF
CANCER–Trevor Hince, Omar Yoder and Herbie Newell
Tom Connors was an advisor, supporter and friend of the Cancer
Research Campaign (CRC) for over 30 years serving as a member
and/or Chairman of the Scientific, Phase I/II Clinical Trials and
Gibb Fellowship Committees. In recognition of his life-time
contribution he was made an Emeritus Fellow of the CRC in
1998. The first meeting of the Phase I/II Committee was held in
July 1980. The second meeting in October 1981 set itself the
challenge of selecting no fewer than 20 compounds for clinical
trials in 2 years with what is, by current standards, a very modest
funding of d41000 (B$ or Euro 60000) per annum. At the outset,
the Committee identified four key needs that were major barriers
to academic cancer drug development:
  To stimulate the submission of compounds for Phase I testing.
  To simplify and provide access to preclinical toxicology.
  To develop clinically tractable formulations for new drugs that
complied with regulatory requirements.
  To open a dialogue with the Committee on Safety of Medicines
in order to establish a legal framework within which clinical
trials with academic drugs could be undertaken.
By December 1983 the Phase I/II Committee was able to report
to the CRC Scientific Committee that two compounds had entered
clinical trials and nine were undergoing preclinical development,
and a Clinical Data Centre directed by Edward Newlands had been
established at the Charing Cross Hospital. In the intervening 20
years, the Committee has selected 89 agents for clinical trials: 25
cytotoxic agents, five antiendocrine drugs, 28 small molecules with
novel or unknown mechanisms of action, five polymer-targeted
agents and 26 antibody-targeted agents/immunotherapies. To date,
four agents have progressed to the market with two, temozolomide
(I–Temodal
s) and 4-hydroxyandrostenedione (II–Lentaron
s),
being particularly successful and many more showing promising
activity in Phase I, II and III trials.
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www.bjcancer.comAlthough Tom never worked outside the UK, he was in every
sense a truly international scientist. In particular, his long
association with the National Cancer Institute, US (NCI) began
in 1966 at the Ninth International Cancer Congress in Tokyo when
he met John Venditti, who was then chief of drug evaluation
at the NCI. In the years that followed Tom became a key
adviser to the NCI’s developmental therapeutics and toxicology
programmes. He paved the way for the NCI’s highly successful
international alliances, and initiated the collaboration with the
CRC.
Tom had the distinction of being the first ‘international figure’
to serve on the NCI’s top scientific advisory and oversight
committees. He also freely offered his wise counsel and expert
knowledge to the NCI in-house panels, programme directors and
countless collaborators and colleagues. It was through his efforts
that the NCI was able to convince the FDA to take a more open
view on approving IND applications for anticancer drugs from
expert groups in Europe and the UK.
When the NCI launched its European Programme and opened
the Brussels Office in 1972, Tom became the principal adviser in
planning its long-term strategy. He fostered a highly successful
transatlantic collaboration and helped the NCI bridge the gap with
Eastern Europe, and establish links with the European Organisa-
tion for Research and Treatment of Cancer (EORTC). Through his
efforts, the NCI was by now well represented in the EORTC drug
development groups and its programme for developing new
European anticancer agents rapidly gained momentum. Given this
flow of new compounds from European sources to the NCI, on
Tom’s advice, the NCI established a testing laboratory at the
Institut Jules Bordet in Brussels to screen new agents. By the late
1970s, tens of thousands of new molecules had been tested by NCI
Brussels and new agents active in the screens were selected for
clinical trials.
Although anticancer drug development was well underway in
Europe, the scientists with expertise in experimental therapeutics
were predominantly from one country, the UK. Therefore, Tom
saw the opportunity to establish a drug development network in
the UK and presented his plan to the NCI. It was viewed with
favour and NCI compounds were selected for consideration by the
CRC Phase I/II Committee. Until that time it had been
inconceivable for the NCI to give new active compounds from its
screens to ‘offshore developers’ and no other individual deserves
more credit in setting the stage for the NCI’s early international
success in anticancer drug research. He was a facilitator, a trusted
colleague and collaborator, inspiring all who surrounded him. He
lived the working philosophy that he taught: ‘Science should be
both satisfying and fun; any new findings must be shared, openly
exchanged, and credit given where due.’
Tom was also an active member of the EORTC for many years,
being elected Chairman of the Laboratory Research Division in
1993, as well as the EORTC Board from 1991 to 1996. Tom saw the
success of the CRC Phase I/II Clinical Trials Committee as a model
on which to build and encouraged close collaboration, under the
umbrella of the tripartite CRC/NCI/EORTC agreement, with
European drug developers across the continent.
CANCER DRUG DEVELOPMENT IN THE UK IN THE
ACADEMIC SECTOR
The Cancer Research UK Drug Development Office–David Secher
and Sally Burtles
The Drug Development Office (DDO) was set up in 1992 in order
to introduce internationally accepted quality standards into Phase
I/II Committee trials to ensure that the data produced by the
Committee would be acceptable to the pharmaceutical industry. It
was anticipated that, if Phase I/II Committee trials were carried out
to Good Clinical Practice (GCP) standards, then time, money and,
ultimately, patients’ lives could be saved, and Tom Connors was
pivotal in having this vision.
To illustrate the importance of performing studies to appro-
priate standards, it is instructive to consider the case of
temozolomide. As described below, temozolomide was discovered
by Malcolm Stevens and colleagues at Aston University. The drug
was taken through preclinical development and then tested in
Phase I and II clinical trials by the Committee. In 1992, the Phase I/
II Committee completed the Phase I trial of temozolomide that
established the maximum tolerated dose (MTD), its toxicity profile
and a recommended dose for Phase II studies (Newlands et al,
1992). After demonstrating the utility of temozolomide in patients
with glioma, the drug was licensed to Schering-Plough, who felt it
necessary to repeat the studies performed by the Phase I/II
Committee before embarking on pivotal Phase III trials (Dhodap-
kar et al, 1997). These studies identified the same MTD, toxicity
profile and recommended dose. Had the Phase I/II Committee
trials been done to GCP, temozolomide, now Temodal
s, could
have been launched 2 years earlier, and more patients could have
benefited from its treatment.
Learning from this experience, and recognising the need to
undertake clinical studies to contemporary regulatory standards,
the DDO was set up to implement systems to ensure that trials are
carried out to ICH-GCP (International Committee on Harmonisa-
tion of GCP) standards. In 2000, the DDO volunteered for a GCP
inspection by the Medicines Control Agency and, while identifying
areas for improvement, the inspection was a resounding success.
In 2001, the European Union (EU) published a Directive on
clinical trials that will be implemented by May 2004. The key issues
for Cancer Research UK in complying with the European Directive
(European Parliament, 2001) are that all trials are to be undertaken
to GCP, all products are to be made to Good Manufacturing
Practice (GMP) standards in a licensed facility, and the option of
performing clinical trials in the UK under a Doctors and Dentists
Exemption (DDX) will no longer be available.
The GCP requirement has enormous implications for academic
clinical research in general. However, it is likely to be less of an
issue for Phase I/II Committee trials as the DDO already largely
operates to these standards. GCP standards also cover laboratory
studies undertaken as part of clinical trials and, in anticipation of
this, Cancer Research UK has employed a Quality Assurance
Manager to ensure that laboratory data are also generated to the
required standards.
In addition to providing access to preclinical toxicology (see
below) and high-quality clinical trials management, Cancer
Research UK can produce both small molecule products and
biological agents to GMP or equivalent standards. The Cancer
Research UK Formulation Unit at the University of Strathclyde is
already licensed to manufacture clinical trials material, and the
Biotherapeutics Development Unit at the Cancer Research UK
London Research Institute (Clare Hall) will also be licensed before
the EU legislation is implemented.
The loss of the DDX is potentially the biggest threat to academic
drug development and early clinical trials in the UK. The details of
the requirements for the new legislation are still unknown, but will
almost certainly entail more extensive preclinical testing than
currently undertaken by Cancer Research UK. While any
additional work can be performed, it may increase the costs
significantly and delay the clinical evaluation of new treatments.
The additional studies are also likely to involve more experiments
in animals, and may require studies in non-rodent species. As
discussed below, the Phase I/II Committee has pioneered the use of
rodent-only toxicology, an issue that Tom felt passionate about,
and any move towards the use of more laboratory animals,
particularly non-rodents, should only be countenanced if there is
an unequivocal scientific rationale.
Recent advances in molecular genetics, and the improved
understanding of the pathology of cancer that these advances
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cancer treatment. Since these therapies are designed to be selective
for specific molecular pathologies they will need to be evaluated in
genetically defined subsets of patients. As discussed below, the
development of ‘targeted therapies’ will throw up many new
challenges for the drug development community. Thanks to Tom’s
vision, the Cancer Research UK DDO is well placed to respond and
continue to be a leader in anticancer drug development in this new
millennium.
In vivo tumour models and preclinical toxicology studies–John
Double and Herbie Newell
For a candidate drug to be considered for clinical evaluation, it is
mandatory that there is a reasonable expectation that biological
activity will be seen in patients at tolerated doses. In vivo tumour
models are used to demonstrate that activity can be achieved in
rodents, normally mice, bearing either rodent or human tumours.
In the era of cytotoxic drug development, tumour growth
inhibition and regression was the biological end point most
frequently used in preclinical studies. However, with the advent of
targeted therapies, mechanistic studies have replaced tumour
growth inhibition as the primary in vivo preclinical end point.
Thus the initial objective of mechanistic in vivo studies is to show
that a drug can interact with its intended target at tolerated doses.
If target interaction can be shown, a link to the desired biological
effect of the agent is sought, for example inhibition of tumour
growth, invasion, angiogenesis or metastasis for which orthotopic
models are now widely used. In addition, the availability of mice
with targeted gene disruption (knockout mice) or gene insertion
(knockin mice), as well as the use of tumours with defined
molecular genetics, means that host–tumour interaction can be
studied in robust and predictive models.
The introduction of high-throughput screening has also been an
important development in cancer drug discovery, and the NCI in
vitro cell line panel has become a particularly valuable resource
(Monks et al, 1997). However, the compounds identified still have
to demonstrate activity in an appropriate in vivo model. Because of
the large number of compounds that can be identified by in vitro
screening strategies, the use of conventional tumour models is not
appropriate, since large numbers of animals would be required. To
address this problem, the in vivo hollow fibre model has been
developed and this can complement mechanism-based in vivo
models in preclinical drug development (Hollingshead et al, 1995;
Suggit et al, 2002).
The preclinical data package for therapies considered by the
Cancer Research UK Phase I/II Committee, and more recently the
New Agents Committee, requires:
  A description of the drug target and how it has been validated.
  Information on the mechanism of action of the new agent.
  Evidence that the drug has activity in an in vivo model at
tolerated doses and details of the pharmacokinetics of the agent
at active doses.
  Experimental data to show that biological activity is linked to
the proposed mechanism of action.
  Details, preferably supported by validation data, of how the
pharmacokinetics and pharmacodynamics or immunodynamics
of the agent will be studied in the clinical trial.
If these data are felt to be robust, the agent is selected for clinical
trials prior to which key preclinical development steps are
undertaken. The resources to complete these preclinical steps,
notably toxicology and bulk manufacture/formulation, were
provided for the first time in a noncommercial setting in the UK
by the Phase I/II Committee in 1980. Toxicology in particular can
be a contentious issue, and at the time the Committee was
established, lengthy and expensive protocols, often involving large
numbers of animals, rodent, non-rodent and even primates, were
standard practice. With Brian Fox, Tom developed simplified
rodent-only toxicology protocols (EORTC/CRC, 1990) and these
were used until 1995. A recent review of the data on the first 25
compounds to be studied (Newell et al, 1999) confirmed that
rodent-only toxicology provides a safe Phase I trial starting dose
and predicts toxicity for the vast majority of the agents
investigated. These data were considered by the European
Medicines Evaluation Agency Committee on Proprietary Medicinal
Products (EMEA CPMP) Safety Working Party, and contributed to
the guidelines that include the use of rodent-only toxicology
studies for first-in-human trials with direct acting anticancer
agents (European Agency for the Evaluation of Medicinal
Products, 1999). Subsequent toxicology studies performed by the
Phase I/II Committee have focussed on the development of
compound-orientated protocols in which the intended clinical
route and schedule of administration is mirrored as closely as
possible in the preclinical safety studies (Burtles et al, 1995). This
approach, coupled with innovative clinical trial designs that
promote patient enrolment to doses that are likely to be effective,
and the use of clinical centres with proven expertise in early
clinical trials, ensures that the need to select a safe starting dose
and animal welfare issues are appropriately balanced.
Clinical trial design and end points–John Smyth, Ian Judson,
Duncan Jodrell and Pat Price
Early clinical trial design has developed dramatically over the past
20 years, and in particular, end points in Phase I trials have
changed from toxicity to pharmacodynamics. Although safety
remains paramount, the recognition that response does not relate
directly to toxicity even with conventional cytotoxic drugs such as
carboplatin (Jodrell, 1999), resulted in a reappraisal of the
objectives and design of early clinical trials. Apart from the
simplistic appeal of end points other than toxicity (trials ‘designed’
to make patients sick are unacceptable ethically), targeted
therapies are in many cases predicted to require long-term
administration so that traditional Phase I trial end points of
MTD and dose-limiting toxicity have been replaced by the optimal
biological dose and pharmacodynamics/immunodynamics. The
optimal biological dose can be defined as that which results in drug
levels in the blood and/or tumour, which produced activity in
preclinical models, the maximal change in the level of a surrogate
marker or, if it can be measured directly, the desired clinical effect.
Once the optimal biological dose has been identified, Phase II trials
can be performed and historically these have used response rates
as a surrogate marker for patient survival. A key recent additional
component of Phase II trials is to define the presence of the drug
target in the tumour and to relate target levels to clinical activity.
Such analyses have been pivotal to the development and
subsequent clinical use of drugs such as trastuzumab and imatinib,
and are now included wherever technically feasible in both Phase I
and Phase II trials.
In addition to providing proof of principle at an early stage of
the clinical evaluation of a compound, knowledge of the time
course and dose dependency of pharmacodynamic effects can help
to optimise scheduling. A good example comes from the Phase I/II
Committee trial of the thymidylate synthase (TS) inhibitor
nolatrexed (III–AG337, Thymitaq) where the rapid recovery of
plasma deoxyuridine levels (a surrogate marker of systemic TS
inhibition) at the end of a 24h infusion led to the investigation of 5
day i.v./p.o. and 10 day p.o. regimens (Rafi et al, 1995, 1998; Jodrell
et al, 1999; Hughes et al, 2000). The 5 day i.v. regimen was
ultimately selected for Phase II and Phase III trials.
With targeted agents the challenge is to design and validate
pharmacodynamic markers, and these tend to be compound
specific and often require lateral thinking in order to provide a
clinically feasible assay. An excellent example from the work of the
Phase I/II Committee relates to the Phase I trial of an antagonist of
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(IV–SPAG, Cummings et al, 1999; Clive et al, 2001). In this study,
forearm blood flow/venous plethysmography was used to show
that SPAG levels could be achieved in patients, which blocked
substance P-induced vasodilation.
Pharmacodynamic studies are now a mandatory component of
early clinical trials and, while surrogate markers such as those used
for nolatrexed and SPAG are valuable, direct measures of drug
action in the tumour are preferable. As a consequence, noninvasive
techniques such as magnetic resonance imaging and spectroscopy
(MRI/MRS) and positron emission tomography (PET) have been
developed and are now increasingly used in early clinical trials (see
below). Where it is not possible to develop a noninvasive approach
to pharmacodynamic monitoring, a surgical biopsy can be
required. Invasive surgical procedures require special justification,
and this includes robust preclinical assay validation and, if
possible, demonstration that the pharmacodynamic effect can be
observed in peripheral blood cells in patients at tolerated doses.
Recent Phase I/II Committee studies with 17-allylamino, 17-
demethoxy geldanamycin (17-AAG) (V), an antagonist of the
HSP90 molecular chaperone important in the stabilisation of a
number of oncogenic proteins, has involved surgical biopsy and
the analysis of HSP90 client protein levels following drug treatment
(Banerji et al, 2002). At a dose of 320mgm
–217-AAG clear effects
on Raf-1, HSP70 and CDK4 levels have been seen, and these studies
provide an excellent example of contemporary Phase I trial design.
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Noninvasive techniques are always preferable to surgery, and
the potential of functional imaging using PET was recognised by
Tom Connors in the late 1980s. In 1991, the CRC supported Pat
Price and Terry Jones, at the MRC Cyclotron Unit, Hammersmith
Hospital, to undertake the synthesis of positron emitting forms of
novel antitumour agents undergoing evaluation by the Phase I/II
Committee. The successful synthesis of both
11C-DACA (VI) and
11C-temozolomide (I) led to a number of ‘world-first’ noninvasive
pharmacokinetic and pharmacodynamic studies. Parallel studies
with
18F-fluorodeoxyglucose as an early marker of tumour
response and
11C-thymidine as a measure of TS inhibition
following nolatrexed treatment confirmed the potential of PET as
a noninvasive pharmacokinetic/dynamic tool. Most recently, the
Phase I/II Committee has studied the antivascular agents DMXAA
(VII) and combretastatin A4 phosphate (VIII), and measurements
of tumour blood flow by PET as well as MRI (see below) have been
critical in defining the clinical pharmacodynamics of these
antivascular agents.
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THE EVALUATION OF APPROACHES DESIGNED TO ACHIEVE
TUMOUR SELECTIVE DRUG ACTIVATION AND DELIVERY
Tumour selective drug activation: from aniline mustard to
state-of-the-art bioreductive agents–Paul Workman and Ian
Stratford
One of Tom Connor’s own spectacular successes in elucidating
the mechanism of tumour-specific selectivity involved the over-
expression of a prodrug activating enzyme in certain cancers. In
1965, Tom and Max Whisson reported the regression and cure of
established ADJ-PC5 mouse plasma cell tumours by a single dose
of aniline mustard (IX; Connors and Whisson, 1965a, b). They
showed that the mechanism underlying the extraordinary selectiv-
ity of aniline mustard was its metabolism by hydroxylation and
glucuronide conjugation in the liver, followed by hydrolysis to the
highly reactive and potent metabolite p-hydroxylaniline mustard
in tumours expressing high levels of b-glucuronidase (Connors
and Whisson, 1966; Connors et al, 1973). On the basis of this work,
aniline mustard progressed to clinical trials. The work also led to
the synthesis of the glucuronide, sulphate and phosphate derivatives
of p-hydroxyaniline mustard as prodrugs for tumour-selective
activation in cancers rich in glucuronidase, sulphatase and
phosphatases, respectively (Double and Workman, 1977). One of
the limitations of the approach was the potential for cleavage of the
prodrugs in normal tissues and plasma, as well as for irreversible
inhibition of the activating enzyme (Workman, 1978; Workman and
Double, 1978). Nevertheless, Tom’s work on these and other
tumour-activated prodrugs laid the foundations for the develop-
ment of antibody directed enzyme prodrug therapy (ADEPT)
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and his studies directly relate in concept to the development of
bioreductive prodrugs to exploit tumour hypoxia and the over-
expression of certain reductase enzymes in a high proportion of
cancers.
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Following on from work pioneered by the late Ged Adams, many
attempts have been made to overcome and exploit tumour hypoxia
both because it is a unique feature of tumours, as opposed to
normal tissues, and because hypoxia underlies the radio-resistance
of many solid tumours. The most widely studied class of hypoxic
cell sensitisers, that is agents designed to increase the activity of
radiation and/or drug therapy in hypoxic cells, are the nitroimi-
dazoles. With nitroimidazoles, definition of the relationship
between one-electron reduction potential and the concentration
required for a given degree of enhancement identified optimal
physicochemical characteristics for radiation sensitisation (Adams
et al, 1977). Furthermore, these studies with radiosensitisers led to
the development of bioreductive hypoxic cell cytotoxins with
inherent activity against hypoxic cells (Stratford and Workman,
1998). The aziridinydinitrobenzene derivative CB1954 (see also
below and XV) and the alkylating nitroimidazole RSU1069 (X)
were two compounds identified in early studies, and RSU1069 was
selected for clinical trials by the Phase I/II Committee in 1982, and
completed in 1986. Unmanageable nausea and vomiting was
encountered with RSU1069 (Horwich et al, 1986); however, the
bioreductive cytotoxins tirapazamine and AQ4N (XI) (Patterson
and McKeown, 2000), the latter currently in clinical trials through
the Phase I/II Committee, testify to the continued interest in the
area of hypoxia-directed therapy. Tirapazamine has reached Phase
III trials where initial results in combination with cisplatin have
been encouraging.
A more sophisticated approach to exploiting tumour
hypoxia is the combination of a therapeutic entity, either a
cytotoxin or a more subtle agent designed to exploit tumour
biology, with an inactivating bio-reductive trigger. Reduction of
the trigger releases the therapeutic entity and studies with
mustard-based systems where the trigger is ‘activated’
by one-electron reduction have resulted in nitrogen:air sensitisa-
tion ratios of 485, vs 1.5 for the active mustard (McNally et al,
2002).
In the development of hypoxia-targeted therapies, an ability to
measure tumour oxygen tension in clinical trials is essential, in
order to explore relationships between any efficacy observed and
the degree of tumour hypoxia. Both invasive studies on tumour
biopsies (ie immunohistochemical detection of nitroimidazole
binding, eg with pimonidazole and EF5) and noninvasive methods
(ie MRS or PET with fluorinated nitroimidazoles such as SR4554
(XII) have been evaluated. SR4554, has shown considerable
promise in animal models (Aboagye et al, 1997, 1998, Seddon
et al, 2002a) and is currently the subject of a Phase I/II Committee
Phase I trial in which MRS is used in patients to detect SR4554-
derived signal, indicative of tumour hypoxia (Seddon et al,
2002b).
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Tumour hypoxia is now well established as a clinical phenomen-
on, and recent studies have confirmed that the biochemical as well as
physiological consequences of hypoxia offer potential for exploita-
tion in prognosis. For example, demonstration that pimonidazole
staining and expression of the glut-1 glucose transporter, coupled to
the strong relationship between metastasis-free survival in advanced
cervical carcinoma and glut-1 expression (Airley et al,2 0 0 1 ) ,s u g g e s t
a mechanistic rationale for the noninvasive measurement of glut-1
levels by
18F-fluorodeoxyglucose PET scanning.
The development of bioreductive agents as tumour-selective
prodrugs is not solely restricted to the exploitation of tumour
hypoxia. Cancer cells frequently overexpress reductive enzymes,
particularly the quinone reductase DT-diaphorase or NQO1 (Fitz-
simmons et al, 1996). This led to the concept of enzyme-directed
bioreductive drug development (Workman, 1994). A number of
agents undergo activation by NQO1, including the clinically used
agent mitomycin C, simpler quinones such as AZQ, RH1 and EO9,
and also CB1954 (Riley and Workman, 1992; Fitzsimmons et al, 1996;
Sharp et al, 2000, see below). EO9 was developed for clinical trials
under the auspices of EORTC (Hendriks et al, 1993; Plumb and
Workman, 1994). Clinical results were disappointing, probably
because of the rapid clearance of the drug (Workman et al, 1992),
but the agent may find a role in the treatment of DT-diaphorase-rich
bladder cancers by intravesicular administration.
Intriguingly, DT-diaphorase expression was also found to
sensitise cancer cells to the benzoquinone ansamycin 17-AAG
(V; Kelland et al, 1999), which has now entered clinical trial as the
first-in-class inhibitor of the HSP90 molecular chaperone ATPase
activity (see earlier section on clinical trial design and end points).
The mechanism behind this potentiation by DT-diaphorase may
relate to reduction of the benzoquinone, but the mode of action of
17-AAG in DT-diaphorase-rich cells remains HSP90 inhibition,
leading to depletion of oncogenic client proteins and simultaneous
inhibition of the PI3 kinase and RAS-ERK signal transduction
pathways (Kelland et al, 1999; Clarke et al, 2000; Hostein et al,
2001). Tom Connors was initially sceptical about our ability to
fully understand the mechanism of the antitumour action of even
the most exquisitely designed agent (see The Connor’s Rules of
Anticancer Drug Development, Table 1). However, he showed a
keen interest in the new generation of agents, such as 17-AAG and
also imatinib, trastuzumab and Iressa, which are being developed
to exploit the specific molecular pathology of cancer as the basis of
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of this new approach (Workman and Kaye, 2002).
Antibody enzyme prodrug therapy–Caroline Springer and
Richard Begent
Tom Connors saw the potential of selective prodrug activation in
the tumour at a very early stage in his career and was publishing
on the subject in 1969. His interests included nitroreductase and
microsomal activation of cyclophosphamide; however, targeting an
enzyme to the tumour did not become feasible until the 1980s
when Ken Bagshawe’s CRC laboratories at Charing Cross Hospital
described antibody-directed enzyme prodrug therapy (ADEPT)
(Bagshawe, 1987; Bagshawe et al, 1988). The Phase I/II Committee
chaired by Tom, encouraged clinical trials of ADEPT on the
mechanism of action of the components to show whether
conditions for effective therapy were being achieved.
The ADEPT approach separates the cytotoxic prodrug from the
targeting antibody in a two-phase system that has benefits over a
one phase chemoimmunoconjugate, immunotoxin or radioimmu-
noconjugate. The antibody binds to an antigen that is preferen-
tially expressed on the surface or in the interstitial spaces of the
tumour cells. The antibody–enzyme complex is administered and
allowed to accumulate at the tumour site. Time is allowed for the
clearance of the conjugate from blood and normal tissues. Then, a
latent nontoxic prodrug is administered, which is converted
selectively by the enzyme at the tumour site into a low molecular
weight toxic drug (Bagshawe, 1987; Bagshawe et al, 1988). The
amplification feature inherent in the enzyme of the conjugate
molecule system means that one molecule of enzyme can catalyse
the conversion of many molecules of the prodrug into the
cytotoxic drug, and thereby provides major advantages. Further-
more there is a bystander effect, whereby those cells that are not
targeted by the antibody–enzyme conjugate are killed by drug
released from neighbouring cells that have been targeted.
The ADEPT approach was initiated using alkylating agent-
derived prodrugs (Bagshawe et al, 1988, 1991; Mann et al, 1990;
Springer et al, 1990) and carboxypeptidase G2 (CPG2) as the
activating enzyme (Melton et al, 1990). The rationale for the use of
alkylating agents as drugs in this approach was that:
  The active drugs show cell-cycle-independent activity.
  The drugs exhibit a dose-dependent effect and are active against
quiescent cells.
  The active drugs induce less acquired resistance than other
classes of chemotherapeutic agents.
  Chemical deactivation is possible by functional groups that are
cleavable by appropriate conjugated enzymes.
  Differences of greater than 100-fold in chemical reactivity
between the prodrug and active drug can be achieved.
  Active drugs with very short half-lives can be designed.
In order to derivatise the nitrogen mustard drugs into prodrugs
for activation by CPG2, an amidic cleavable bond was introduced
between the mustard aromatic ring and a glutamic acid moiety. An
advantage of this system was that the prodrug uptake into cells (ie
penetration across cell membranes) could be minimised due to the
two acidic functional groups of the glutamate in contrast to that of
the active drug, which is more lipophilic. This was the rationale for
the synthesis of a series of L-glutamyl amides of nitrogen mustards
derived from 4-aminobenzoic acid, notably the CMDA prodrug
(XIII) (Mann et al, 1990; Springer et al, 1990), and after cleavage of
the amide bond by CPG2 the resulting drugs become more
reactive. Further studies of this ADEPT system demonstrated its
ability to achieve both the ablation of chemo-resistant CC3
choriocarcinoma human tumour xenografts in nude mice (Spring-
er et al, 1991) and growth delays of OvCa-433 ovarian human
tumour xenografts (Sharma et al, 1994).
Pilot scale ADEPT clinical trials demonstrated the feasibility of
the approach (Bagshawe et al, 1991, 1994; Bagshawe, 1995; Napier
et al, 2000). However, the system was complex, the antibody–
enzyme conjugate difficult to make reproducibly, and the antibodies
and enzymes were immunogenic, preventing more than two or three
administrations even with immunosuppressive therapy. These
problems have been addressed by making a genetic fusion protein
of a single chain Fv (sFv) (Begent et al, 1996) antibody with CPG2
(Bhatia et al, 2000). The design features of this molecule include
phage library-derived sFv antibody of appropriate affinity linked to
CPG2 enzyme, low immunogenicity, dimeric structure, stability in
vitro and in vivo, therapeutic levels of enzyme localising to tumour,
clearance from normal tissues in both mice and man due to
glycosylation (by fermentation in Pichia pastoris), low toxicity, and
prodrug activation with therapeutic activity.
All of these features have now been achieved. The fusion protein,
MFE23-CPG2 gives tumour to normal ratios of 100–1000 to 1 in an
animal tumour model without a separate clearance system. Human
colon carcinoma xenografts show tumour regression without
significant toxicity and this fusion protein is now being used with
the bis-iodo-phenol mustard prodrug (ZD2767P, XIV) in a Cancer
Research UK Phase I/II trial. Further bioinformatics-led engineer-
ing of the enzyme and antibody are in progress to reduce
immunogenicity (Boehm et al, 2000; Spencer et al, 2002).
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Table 1 The Connors rules of anticancer drug development
1. Scientists under the age of 40 believe that cancer research began around
1975
K It was around 1975 that computerised data searches became generally
available
2. Anticancer agents based on an elegant working hypothesis are sometimes
successful in the clinic
K However, the way they act is often nothing to do with the working
hypothesis
3. There is no direct correlation between the elegance of a working
hypothesis and success in the clinic
K Some cynics believe the correlation is inverse
4. Results obtained using isolated systems, for example receptors, do not
extrapolate readily to cells in culture
K Results obtained using cells in culture do not extrapolate readily to in
vivo systems, for example rodents with tumours
K Results using rodents with tumours do not extrapolate readily to the
clinical situation
5. State of the art technology is vitally important for cancer research
K State of the art technology complements rather than substitutes for
innovative thinking
6. How to keep happy (adapted from an old Chinese proverb)
K For one day, get drunk
K For one week, kill a pig
K For one month, get married
K For a lifetime, do cancer research
Personal communication from Professor Tom Connors presented in his George and
Christine Sosnovsky Award Lecture, Forty Years of Cancer Research (1999).
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work performed by Tom Connors on nitrogen mustard drugs now
show great promise for development of a practical ADEPT system
for the first time.
CB1954 : from the Walker tumour to NQO2 and gene-directed
enzyme prodrug therapy (GEDPT)—Richard Knox and David
Kerr
A common theme throughout Tom Connors’ research career was
the search for antitumour specificity, and CB1954 (XV) is a rare
example of a compound that shows outstanding tumour selectivity.
Whilst chemically only a monofunctional alkylating agent (by
virtue of its single aziridine function), CB1954 exhibited a dramatic
curative and highly selective action against the Walker 256 rat
tumour with the highest therapeutic index of any compound
studied (TI¼70) (Cobb et al, 1969; Connors and Melzack, 1971). It
was subsequently shown that Walker cells could bioactivate
CB1954 by aerobic reduction of the 4-nitro group to the
corresponding hydroxylamine, which rapidly acylated to a
bifunctional alkylating agent (Roberts et al, 1986; Knox et al,
1988b, 1991). The enzyme responsible for reducing CB1954 in rat
tissues is DT-diaphorase (NQO1, NAD(P)H dehydrogenase (qui-
none) (Knox et al, 1988a); however, the human form of
DT-diaphorase metabolises CB1954 much less efficiently than rat
DT-diaphorase (Boland et al, 1991), and even cells that are high in
human DT-diaphorase are insensitive to the drug (Boland et al,
1991; Mehta et al, 1999).
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Given the limited ability of human NQO1 to activate CB1954, the
drug became an ideal candidate for gene therapy in which the gene
delivered to the tumour is an NQO1 that can activate CB1954.
Escherochia coli nitroimidazole reductase (nitroreductase, NTR)
can bioactivate CB1954 much more efficiently than even rat DT-
diaphorase (Knox et al, 1992) and human tumour cells transduced
with retroviral vectors to express this enzyme are very sensitive to
the drug (Bridgewater et al, 1995; Bailey et al, 1996; Green et al,
1997; McNeish et al, 1998). It was shown that NTR-expressing cell
lines are 500–2000-fold more sensitive to CB1954 than parental
cell lines (Green et al, 1997; McNeish et al, 1998). Importantly, a
strong bystander effect operates and, with only 5% of cells
transfected, high levels of total cell kill (490%) were observed
(McNeish et al, 1998) with similar efficacy in vivo (Weedon et al,
2000).
Phase I clinical trials, initially with a viral gene vector and
CB1954 being administered as single agents have been performed,
with the intention of combining the agents once adequate tumour
expression of NTR has been documented following intratumoral
virus injection. CB1954 was administered by i.v. injection every 3
weeks, or i.p. followed by 3-weekly i.v. injections, up to a
maximum of six cycles. The CB1954 dose was escalated from 3
to 37.5mgm
–2, at which point dose-limiting diarrhoea and hepatic
toxicity was seen. CB1954 was well tolerated at a dose of 24mgm
–2,
and sufficient serum/peritoneal levels are achieved for an enzyme–
prodrug approach to be feasible (Chung-Faye et al, 2001).
More recently, NTR-expressing replication-deficient adenovirus
(under the control of the CMV promoter) has entered trial in
patients with resectable liver cancer. Virus is administered 2–4
days preoperatively by intratumoral injection and the kinetics of
virus distribution, NTR expression, virus shedding and the
appearance of neutralising antibodies is being assessed. So far,
12 patients have been entered and virus dose has been escalated
from 10
8 to 10
11 virus particles without any serious toxicity.
As an alternative approach to the use of CB1954, it has recently
been shown that there is potent endogenous CB1954-reducing
activity in human tumour cells (Wu et al, 1997), although
reduction is only detected in the presence of the cosubstrate
dihydronicotinamide riboside (NRH). The latent activity is due to
an endogenous enzyme designated NAD(P)H quinone oxidore-
ductase 2 (NQO2) (Wu et al, 1997), which can be considered as a
human NRH-dependent nitroreductase (Knox et al, 2000a). A
simple reduced pyridinium derivative designated EP-0152R can,
like NRH, act as cosubstrate for NQO2, and CB1954 is an effective
antitumour agent when given with EP-0152R in vivo against
experimental human tumour xenografts (Knox et al, 2000b).
Given the provenance of CB1954, the apparently favourable
distribution of NQO2 in certain tumour types and the lack of acute
toxicity of EP-0152R, NQO2 represents a promising novel target
for antitumour prodrug therapy. A Phase I clinical trial combining
CB1954 with EP-0152R is due to start in 2003. CB1954 has been
described as ‘a drug in search of a human tumour to treat’
(Workman et al, 1986a, b). The GDEPT and NQO2 studies
described above may allow this vision to be realised.
Polymeric drug delivery–Ruth Duncan and Jim Cassidy
Alongside attempts to find novel tumour-specific targets, a variety
of technologies have been developed for the improved delivery or
targeting of existing and new drugs to tumours. Increased
localisation in tumour tissue (410-fold) should theoretically
overcome drug resistance. Furthermore, ‘steering’ chemotherapy
away from normal tissues should reduce toxicity.
The use of polymer–drug conjugates for tumour targeting
combines the versatility of polymer and organic (peptide and
medicinal) chemistry to allow optimisation of the macromolecular
prodrug design. It also takes advantage of passive tumour targeting
as the result of the enhanced permeability of angiogenic vessels,
the enhanced permeability and retention (EPR) effect (Matsumura
and Maeda, 1986). Both conventional chemotherapeutics and
drugs designed to interact with novel targets can be polymer-
bound. In theory, the construct can also incorporate ligands to
facilitate receptor-mediated tumour targeting (Duncan and Kope-
cek, 1984; Duncan et al, 1986; Duncan, 1992; Duncan and
Spreafico, 1994; Brocchini and Duncan, 1999). The original model
proposed by Ringsdorf (1975) envisaged a hydrophilic polymer
backbone chosen to aid drug solubilisation, a biodegradable
polymer–drug linker designed to ensure stability in the circula-
tion, and a targeting ligand to promote tumour-specific delivery.
Required conjugate characteristics are now well established. The
polymer backbone must be nontoxic and nonimmunogenic, must
have sufficient drug-carrying capacity and preferably be biode-
gradable to ensure eventual elimination. If the backbone is not
degradable the molecular weight should be limited to o40000Da
to ensure eventual renal elimination.
Polymer conjugation is also an attractive opportunity to
solubilise poorly water-soluble drugs (Caiolfa et al, 2000). Drug
conjugation limits cellular uptake to the endocytic route, and once
internalised the conjugate is trafficked via the endosomal
compartments (acid pH 6.5–5.5) to lysosomes and thereby
exposed to pH B5.0 and an array of lysosomal hydrolases, that
is lysosomotropic delivery. The polymer–drug linkage must be
completely stable in transit, not degrading too rapidly in the
bloodstream or during renal excretion—the primary route of
elimination. Extensive studies involving HPMA copolymers
bearing libraries of model peptidyl linkers (reviewed in Duncan,
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British Journal of Cancer (2003) 89(3), 437–454 & 2003 Cancer Research UK1992) enabled design of the tetrapeptide linker Gly-Phe-Leu-Gly
cleaved by the lysosomal cysteine proteases originally used for
doxorubicin conjugation (XVI–PK1 (FCE28068)). Recently, a
combination of a peptide linker and a terminal ester bond was
used to synthesise an HPMA copolymer conjugate of paclitaxel and
camptothecin (Meerum Terwogt et al, 2001) and a variety of
platinum-binding ligands including a pendant diamine, malonate
and simple carboxylate were used to generate a family of HPMA
copolymer platinates (Gianasi et al, 1999). Whereas the malonate
and carboxylate released biologically active platinum species
hydrolytically, the HPMA copolymer-Gly-Phe-Leu-Gly-ethylene-
diamine-platinate required enzymatic cleavage.
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Tumour-specific (or tumour-enhanced) receptors appear to
offer the most elegant opportunity for targeted delivery. Although
a vast array of putative tumour targeting residues have been
investigated, so far the only ‘targeted’ conjugate to enter clinical
testing is an HPMA copolymer–doxorubicin conjugate containing,
additionally, galactosamine (XVII, PK2 (FCE28069)). This con-
jugate was designed (Duncan et al, 1983, 1986) to target the
asialoglycoprotein receptor present on normal hepatocytes and
hepatocellular carcinoma with the hope of improving treatment of
primary and secondary liver cancer. Liver targeting of this
conjugate has been verified by clinical gamma camera imaging
(Seymour et al, 2002).
The Phase I trial of PK1 was performed in 1994–1995 (Vasey
et al, 1999). It was possible to escalate the doses of doxorubicin to
levels four-fold higher than those of free doxorubicin. Importantly,
no polymer backbone-related toxicity was encountered and no
cardiac effects were noted despite the high levels of doxorubicin-
equivalents being given. Pharmacokinetic studies confirmed that
PK1 was acting as a depot within the circulation with terminal half-
lives of 93h for total doxorubicin and 108h for doxorubicin itself.
Studies with
131I-labelled PK1 showed evidence of tumour drug
uptake in some patients. Notably, anticancer activity was
demonstrated in this trial, including patients with anthracycline-
resistant breast cancer. Overall, the trial addressed many of the
outstanding questions in the field and opens the area to new
polymeric agents.
PK1 has subsequently undergone Phase II evaluation in color-
ectal cancer (as an example of an anthracycline-resistant cancer),
in non-small-cell lung cancer, and in breast cancer patients (both
anthracycline naive and anthracycline resistant). These studies are
currently being concluded and it is clear that PK1 has no activity in
colorectal cancer but some activity in NSCLC. Further studies are
required to elucidate the magnitude of the activity of PK1 in
NSCLC in comparison to that of free doxorubicin.
In a Phase I trial, PK2 was shown to produce significant
targeting to both normal liver and hepatic tumours with partial
clinical responses (Seymour et al, 2002). A Phase II evaluation of
PK2 in hepatocellular carcinoma is planned.
Phase I/II/III studies are also ongoing with the polyglutamate
(PGA)-paclitaxel conjugate CT-2103 (Bolton et al, 2002; Sabbatini
et al, 2002). The drug is linked through the 20 position via an ester
bond to a biodegradable PGA polymer of B80000Da molecular
weight. A significant number of patients have displayed partial
responses or stable disease (ovarian, colorectal, NSCLC) both with
CT-2103 alone and when combined with cisplatin or carboplatin
and patients with paclitaxel-resistant ovarian cancer have shown
responses. Lastly, HPMA copolymer-platinate (AP5280), PEG-
camptothecin and polysaccharide–camptothecin polymeric anti-
tumour agents have also commenced Phase I trials, and the results
are awaited with interest.
Tom Connors strongly supported the development of a
completely new class of antitumour compounds in the form of
polymer–drug conjugates. Thanks to his support, the field is now
well-established with 11 compounds, plus two imaging agents, in
clinical trials.
SELECTED ACTIVITIES AND ACHIEVEMENTS OF
THE CANCER RESEARCH UK PHASE I/II COMMITTEE
Chemistry-driven drug discovery–N-methylformamide to
Phortress–Malcolm Stevens and Edward Newlands
Among the outstanding successes of the Phase I/II Clinical Trials
Committee as a mechanism for the evaluation of new anticancer
agents and diagnostics, is the development of the methylating
agent temozolomide (I–Temodal
s) (Stevens and Newlands, 1993;
Newlands et al, 1997). This drug arose as a result of multi-
disciplinary research in which interaction between medicinal
chemists and pharmacologists was critical. Temozolomide was
selected from a group of imidazotetrazine derivatives synthesised
by Stevens and colleagues. The lead compound mitozolomide had
shown unpredictable and severe myelosuppression in the clinic
(Newlands et al, 1985) whereas in murine toxicology studies
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also shown to be schedule dependent in its antitumour activity.
The early clinical trials of temozolomide, conducted by the Phase I/
II Committee, were performed with extensive laboratory input,
pharmacokinetic studies in particular, to establish the optimum
route, schedule and dose of administration (Newlands et al, 1992).
The Phase I/II Committee looked at neoadjuvant temozolomide
given postsurgery and preradiotherapy in patients with high grade
gliomas. In vitro experiments confirmed that temozolomide was
additive when combined with radiation in glioma cell lines in
tissue culture. A continuous schedule of temozolomide was
developed to be given throughout the patient’s radiotherapy; this
was shown to be safe and active in patients with glioma.
The mechanism of action of temozolomide was studied using
11C-labelled temozolomide PET scanning and pharmacology
(Newlands et al, 1997) confirming that the
11C label in the methyl
position was retained by glioma tissue in patients. In contrast, a
tracer dose of
11C-temozolomide, labelled in the carbonyl position
largely appeared in the patient’s breath as exhaled CO2.
Since Schering Plough took over the development of temozo-
lomide they have performed registration trials in patients with
high-grade glioma leading to the licence of temozolomide in the
USA and Europe in 2000. There is considerable interest in looking
at more extended treatment delivery schedules, drug combinations
and combining temozolomide with radiation in patients with brain
metastases from tumours outside the central nervous system. Of
particular interest is the recent EORTC randomised trial compar-
ing surgery and radiotherapy in one arm, with surgery, radio-
therapy and continuous temozolomide in the second arm for
patients with glioblastomas. In total, 573 patients were accrued in
approximately 24 months to March 2002 and the results are eagerly
awaited. Experimentally, the antitumour activity of temozolomide
is increased in the presence of some DNA repair inhibitors, in
particular the alkyltransferase inhibitor PaTrin 2, and clinical trials
of temozolomide plus Patrin 2 are also ongoing.
In addition to temozolomide, the group led by Malcolm Stevens,
at Aston University and at the University of Nottingham, have
been responsible for the development of four clinical trial
candidates. These are N-methylformamide (XVIII) (McVie et al,
1984), mitozolomide (XIX) (Newlands et al, 1985), MZPES (XX)
(Stuart et al, 1989) and Phortress (XXI) (Bradshaw et al, 2001,
2002). The latter compound exemplifies perfectly how a novel
chemical with interesting pharmacological properties (ie exquisite
selectivity for a small number of tumour cell lines in vitro) can be
used to unravel fascinating biology (ie binding to the arylhydro-
carbon receptor, cytochrome P450 1A1 induction, and activation
to a highly potent DNA-reactive species), which ultimately results
in a clinical trial candidate. The clinical trial with Phortress,
planned for 2003, will contain the full spectrum of translational
research aimed at confirming the mechanism of action in patients
that has been comprehensively defined by Tracey Bradshaw and
colleagues in their preclinical studies (Chua et al, 2000; Bradshaw
et al, 2001; Loaiza-Perez et al, 2002).
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Platinum complexes: cisplatin to BBR3464–Hilary Calvert and
Eve Wiltshaw
The platinum complexes cisplatin (XXII) and carboplatin
(XXIII) are among the most successful anticancer agents
developed. Their curative activity is seen in testicular teratoma
and certain paediatric solid tumours, as well as significant
effects against a broad spectrum of more common malignancies,
notably ovarian cancer, head and neck cancer, and small cell
and nonsmall cell lung cancer. Tom Connors was among the
first to study the activity of platinum complexes in preclinical
tumour models (Connors et al, 1972). Sir Alexander Haddow,
recognising the potential importance of this new class of drugs,
encouraged the initiation of clinical trials with cisplatin at the
Royal Marsden Hospital in 1972 by Eve Wiltshaw. These early
clinical trials identified activity in patients with relapsed ovarian
cancer although the toxicities were also severe–profuse nausea
and vomiting, and renal failure. The advent of 5-hydroxytrypa-
mine receptor type 3 antagonists and the use of hydration/
diuresis has largely controlled these side effects, respectively.
However, an alternative approach was initiated by Tom Connors
and Ken Harrap which resulted in the identification of
carboplatin as an equiactive yet non-nephrotoxic platinum
complex. The first Phase I trial of carboplatin was completed in
1981 and this identified dose-limiting haematological toxicity,
as well as early signs of activity, but failed to detect any
significant renal side effects (Calvert et al, 1982). The most
important difference between cisplatin and carboplatin is the
30-fold reduced reactivity, which allows renal excretion without
renal damage, as well as reduced emesis and neurotoxicity.
However, whereas carboplatin produces no significant nephro-
toxicity, renal function does have a marked effect on the
haematological toxicity of the drug. Subsequent pharmacoki-
netic studies led to the development of renal function-
based carboplatin dosing using the ‘Calvert’ formula (Calvert
et al, 1989). Using this formula, the absolute dose (in mg)
required for each patient is calculated from the desired target
area under the free carboplatin plasma concentration vs
time curve (AUC–mgml
–1min) and the patient’s absolute
glomerular filtration rate (GFR–mlmin
–1, preferably measured
by an isotopic method and not from serum creatinine
alone):
CarboplatindoseðmgÞ¼TargetAUC ðGFRðmlmin 1Þþ25Þ
Despite the success of cisplatin, and subsequently carboplatin in
which Cancer Research UK scientists played no small
part, the complexes suffered from the problems of inherent
and acquired resistance that has beset all forms of cytotoxic
chemotherapy. In a programme led by Ken Harrap at the
Institute of Cancer Research, London, extensive studies were
undertaken to identify Pt-complexes with a broader spectrum of
activity than cisplatin and carboplatin, and/or activity in
disease resistant to these agents. Two compounds derived from
this programme, JM216 (XXIV) and AMD473 (XXV)w e r e
t a k e ni n t oP h a s eIc l i n i c a lt r i a l sb yt h eP h a s eI / I IC o m m i t t e e .
These trials led to further research with the objective of
demonstrating activity in patients with Pt-resistant tumours,
or tumour types where Pt-complexes are not generally
considered active. Of over 15 complexes studied in clinical
trials, only oxaliplatin has a proven clinical efficacy profile
significantly different from that of the first-generation com-
plexes (cisplatin and carboplatin), in this case activity in
colorectal cancer.
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Most recently, the Phase I/II Committee has completed studies
with the triplatinum complex BBR3464 which has preclinical
activity in a panel of 18 xenograft models that was clearly superior
to that of cisplatin. In particular, BBR3464 was active against
tumours with mutant p53. Despite these clinical data there was
only one partial response in 19 ovarian cancer patients who were
platinum refractory, which again brings into question the value of
preclinical tumour models when used in a screening as opposed to
a mechanistic mode.
Overall, from the early days of cisplatin at the Royal Marsden
Hospital through the development of carboplatin to more recent
clinical trials with second/third-generation complexes, Cancer
Research UK scientists and the Phase I/II Committee have played a
major role in the development of this important class of drugs.
Antivascular agents–Mike Bibby and Gordon Rustin
During tumour angiogenesis endothelial cell division increases
dramatically giving rise to an exploitable feature for therapy
(Denekamp, 1982). A key advantage of targeting the tumour
vasculature is that endothelial cells are genetically stable and hence
are less likely to develop drug resistance. Furthermore, the normal
complement of apoptosis-related genes should still be functional,
which also, in theory, makes the endothelial cell an attractive
target. There are two principal therapeutic approaches by which
the tumour vasculature can be targeted. Firstly, antiangiogenic
strategies, which involve interrupting the actual process of
angiogenesis, and secondly antivascular approaches, which aim
to damage the existing vessels within tumours. The Phase I/II
Committee has now evaluated four antivascular drugs.
Flavone acetic acid ester (XXVI) (NSC 293015, LM985) emerged
as a lead compound from a series of flavonoids from Lyonnaise
Industrielle Pharmaceutique (Lipha) that were screened by the
National Cancer Institute (NCI), and as a result of solid tumour
activity in preclinical models LM985 was selected by the Phase I/II
Committee. However, drug-associated hypotension was encoun-
tered in Phase I trials with LM985 (Kerr et al, 1985). The free acid
flavone acetic acid (XXVII) (NSC 346512, LM975, FAA) was
selected and studied as a back-up (Kerr et al, 1987), as it was
responsible for the antitumour effects seen in mice (Double et al,
1986; Bibby et al, 1987a).
In vitro studies of FAA (Bibby, 1991; Bibby and Double, 1993)
demonstrated that very high concentrations or long exposure
times, in excess of those achieved in vivo, were necessary for direct
cytotoxicity (Bibby et al, 1987) and indicated that an established
blood supply to the tumour was necessary for response (Double
et al, 1986). It became clear that the vascular component was of
major importance for the response of tumours in mice (Bibby et al,
1989; Hill et al, 1989; Zwi et al, 1989). In addition, FAA produced
significant immune effects (reviewed in Bibby and Double, 1993),
and Ching and Baguley (1988) demonstrated that FAA could
enhance the lytic effects of peritoneal macrophages in vitro against
a range of tumour cells. Furthermore, TNFa was implicated as a
major factor in FAA-induced vascular shutdown, and the
haemorrhagic necrosis seen in subcutaneously transplanted
tumours treated with FAA had already been likened to effects
seen after TNFa treatment.
Although these preclinical studies with FAA were exciting, the
drug was consistently inactive in Phase II clinical trials (eg Kerr
et al, 1989), and hence FAA analogues were synthesised in an
attempt to identify an agent that reproduced in humans the effects
seen in mice. A series of analogues with the structurally related
xanthenone chromophore were developed (Atwell et al, 1989;
Rewcastle et al, 1989, 1991a–c), and DMXAA (VII) was identified
as an agent that produced a similar degree of haemorrhagic
necrosis to FAA against the colon tumours but at 10–15-fold lower
doses (Rewcastle et al, 1991c; Laws et al, 1995). As with FAA,
DMXAA produced numerous immune effects in vivo although
these occurred at much lower concentrations. DMXAA was more
potent at inducing expression of TNFa mRNA than FAA in murine
and human cells (Ching et al, 1994). A Phase I trial by the Phase I/
II Committee has shown, using Dynamic Contrast Enhanced MRI
(DCE-MRI), that DMXAA can cause changes consistent with a
maintained reduction in blood flow in tumours, but not muscle, in
patients (Galbraith et al, 2002). Weekly or three-weekly dosing was
well tolerated at doses up to 3700mgm
–2 and, in addition to the
DCE-MRI changes, elevated tumour but not serum TNF levels and
plasma serotonin metabolite levels were observed, consistent with
preclinical data (M Jameson and GJ Rustin, personal communica-
tions). Combination studies with cytotoxic drugs are therefore
planned with DMXAA and the combination with paclitaxel is
particularly impressive in preclinical studies (Siim et al, 2003).
O
O
O
O
N
O
O
OH
O
XXVI XXVII
The fourth antivascular agent to be studied by the Phase I/II
Committee is combretastatin A4 phosphate (VIII) (CA4P). The
combretastatins are a family of compounds derived from the
African tree Combretum caffrum (Pettit et al, 1987, 1989). CA4P is
a relatively simple stilbene that has been shown to interact with
tubulin at or near the colchicine-binding site, resulting in the
inhibition of tubulin assembly and therefore disruption of
microtubular function (McGown and Fox, 1989). Treatment with
combretastatin A4, and its more soluble prodrug CA4P (Pettit et al,
1995), results in vascular shutdown within the tumour causing
massive haemorrhagic necrosis (Dark et al, 1997; Grosios et al,
1999). In animals, CA4P treatment results in significant anti-
tumour effects at less than one-tenth of the MTD (Dark et al,
1997). Early clinical studies by the Phase I/II Committee have
shown that CA4P is well tolerated at doses below 52mgm
–2 but
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including tumour pain, are seen at higher dose levels (Stevenson
et al, 2000). Again a significant reduction of tumour blood flow has
been demonstrated by DCE-MRI and PET, and evidence of
biological activity has been seen (Galbraith et al, 2000). CA4P
combination studies with both cytotoxic agents and radio-labelled
tumour selective antibodies are planned.
The studies with antivascular agents demonstrated the ability of
the Phase I/II Committee to undertake mechanistic early clinical
trials in which pharmacodynamic end points are a key component.
Such studies are essential when the target is tumour blood vessels,
as preclinical studies showed minimal tumour size reduction when
vascular targeting drugs were given alone. To make decisions
regarding further development, especially in combination studies,
it is essential to know whether these drugs are affecting tumour
blood flow in patients.
Antiendocrine agents–Michael Jarman and Charles Coombes
The preclinical and clinical development of antiendocrine agents by
the Phase I/II Committee has variously involved collaborations
between the Institute of Cancer Research, Royal Marsden Hospital,
Imperial College School of Medicine (ICSM) and Charing Cross
Hospital. The approach taken, that is metabolism-directed drug
discovery, began in collaboration with Tom Connors at the Institute
of Cancer Research in the early 1970s, and was later applied to
tamoxifen, targeting the oestrogen receptor, and aminoglutethimide
(XXVIII), which inhibits the aromatase enzyme catalysing the final
step in the synthesis of oestrogens. Aminoglutethimide inhibits this
cytochrome P450 enzyme via its basic amino group, but metabolism
by N-acetylation or N-hydroxylation inactivates it. This inactivation
was circumvented in the pyridyl analogue Rogletimide (XXIX)
(formerly pyridoglutethimide). Unlike aminoglutethimide, Rogleti-
mide selectively inhibited aromatase. In the Phase I trial on 10
patients it reduced circulating oestradiol by 50% at doses above
200mg b.d. (Dowsett et al, 1991). However, rogletimide also induced
its own metabolism, and plasma half-life fell with repeated dose
(Haynes et al, 1991), so that potency was compromised. Aromatase
inhibitors of much greater potency have now superseded Rogleti-
mide. One of these, 4-hydroxyandrosteniodone (II), was synthesised
and tested under the auspices of the Phase I/II Committee back in
1982 and was subsequently licensed to Novartis. It was available in
many countries until this year, when potent third-generation
compounds became available.
Idoxifene (XXX) was developed in response to a perceived need
to block the metabolism of tamoxifen to its 4-hydroxy derivative.
Though binding 100-fold more strongly to the target oestrogen
receptor, 4-hydroxytamoxifen is rapidly cleared via its glucur-
onide. The 4-iodo substituent in idoxifene prevents 4-hydroxyla-
tion and confers an improved binding affinity compared with
tamoxifen. In a Phase I trial on 20 patients (Coombes et al, 1995), it
had a longer half-life than tamoxifen, and evidence of partial
response following relapse on tamoxifen. However a Phase II trial,
comparing idoxifene and tamoxifen, both at 40mg o.d., in 48
postmenopausal patients, who had previously received tamoxifen,
showed oestrogenic side effects and no evidence that idoxifene was
better in this setting.
Abiraterone (XXXI) is a potent inhibitor of the enzyme,
cytochrome P450-17a, that mediates the biosynthesis of the
immediate precursors of the active androgenic steroids testoster-
one and 5 a-dihydrotestosterone (Potter et al, 1995). It could
therefore inhibit both testicular and adrenal androgen biosynth-
esis, producing maximal androgen ablation in the treatment of
hormone-dependent prostate cancer. A Phase I trial (principal
investigators Dr I R Judson and Dr D Dearnaley) evaluating the
prodrug abiraterone acetate in three settings looks encouraging;
(a) single dose in castrate patients, (b) single dose in noncastrate
patients, (c) multiple dose in noncastrate patients.
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Immunotherapies–Peter Amlot and Robert Hawkins
The Phase I/II Committee also has taken on active interest in the
development of immunotherapies, including direct antibody-based
treatments and antibody, DNA and cell-based vaccines.
The advances made possible by the development of monoclonal
antibody biotechnology has allowed the development of reagents
with exquisite specificity for tumour-associated antigens. The
antibodies can be used either in native form, for example, anti-
CD5, CD20, CD21 and CD52 for the treatment of haematological
malignancies, or conjugated to ribosome-inactivating toxins such
as ricin or saporin, to form immunotoxins. The Phase I/II
Committee has recently sponsored trials with an anti-CD19
antibody and an anti-CD38 antibody conjugated to saporin for
the treatment of childhood acute lymphoblastic leukaemia and
multiple myeloma, respectively.
The immunogenicity of murine monoclonal antibodies necessi-
tated the development of humanised or chimeric antibodies.
However, the over-riding problems of toxicity and immunogeni-
city remain significant issues. In particular, vascular leak
syndrome (VLS) is a complex and difficult-to-manage side effect
of immunotoxins. The mechanism underlying this effect is thought
to be the interaction between the toxin moiety and the vascular
endothelium, and a satisfactory way of overcoming this problem
has yet to be defined. Nonetheless the CD22-pseudomonas
exotoxin fusion protein CD22-PE is one of the most effective
treatments for hairy cell leukaemia (Kreitman et al, 2001).
However, the more widespread use of immunotoxins will require
the resolution of toxicity and immunogenicity issues, and in the
meantime alternative antibody therapies such as ADEPT (see
above) may offer more promise.
While vaccination has played a major role in the control or even
eradication of infectious diseases, it has yet to make a major
impact on cancer. Successful vaccination requires a number of
components; namely, a viable tumour antigen, a feasible vaccine
methodology and an understanding of the type of immunity
required to control the tumour. A large number of tumour-
associated target antigens have been identified and these include:
  Oncofoetal antigens: for example carcinoembryonic antigen.
  Differentiation antigens: for example gp100 in melanoma.
  Mutated gene products: for example p53 and ras.
  Viral gene products: for example those produced by human
papilloma virus (cervical cancer), Epstein–Barr virus (Burkitt’s
lymphoma) and hepatitis B virus (hepatocellular carcinoma).
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Compound and mechanism of action CR-UK studies
Current status of agent
(not all CR-UK trials) Reasons for discontinuation
Cytotoxic drugs
1069-C85–tubulin binding agent Phase I Discontinued after Phase I Unacceptable toxicity
AG2034–antipurine antifolate Phase I Discontinued after Phase I Superseded by improved
analogue AG2037
AMD473 (ZD0473)–platinum complex Phase I/II Phase II studies ongoing
Amphetinile–tubulin binding agent Phase I Discontinued after Phase I Unacceptable toxicity
Amsalog–topoisomerase inhibitor (m-AMSA derivative) Phase I (oral) Discontinued after Phase I Poor oral bioavailability
AQ4N–reductively-activated topoisomerase inhibitor Phase I Phase I study ongoing
BBR3464–platinum complex Phase II Discontinued after Phase II Lack of activity
Biantrazole (DUP941/CI941)–topoisomerase inhibitor Phase I/II Registered drug now withdrawn
BZQ–reductively-activated alkylating agent Phase I Discontinued after Phase I Unacceptable toxicity
C6G mustard–carbohydrate-targeted alkylating agent Phase I Discontinued during Phase I Lack of potency
CB10-277–methylating agent (DTIC analogue) Phase I/II Discontinued after Phase II Lack of activity
Clomesone–alkylating agent Phase I Discontinued after Phase I Unacceptable toxicity
DACA–topoisomerase inhibitor Phase I Discontinued after Phase II Lack of activity
Didox–ribonucleotide reductase inhibitor Phase I Discontinued after Phase I Unacceptable toxicity
Etoposide phosphate–etoposide prodrug Phase I Registered drug (Etopophos)
JM216 (satraplatin)–platinum complex Phase I Phase III studies ongoing
Methane dimethane sulphonate–alkylating agent Phase I Discontinued after Phase I Unacceptable toxicity
Mitozolomide–chloroethylating agent Phase I/II Discontinued after Phase II Superseded by improved
analogue temozolomide
MZPES–nonclassical dihydrofolate reductase inhibitor Phase I Discontinued after Phase II Unacceptable toxicity/lack of activity
Nolatrexed (AG337)–thymidylate synthase inhibitor Phase I Phase III study ongoing
RH1–reductively activated alkylating agent Phase I Phase I planning ongoing
Rhizoxin–tubulin binding agent Phase II Discontinued after Phase II Lack of activity
SJG-136–DNA sequence selective minor groove binder Phase I Phase I planning ongoing
Temozolomide–methylating agent Phase I/II Registered drug (Temodal)
Trimelamol–preactivated methylmelamine Phase I/II Discontinued after Phase II Problems with manufacture
Antiendocrine drugs
4-Hydroxyandrostenedione–oestrogen synthesis inhibitor Phase I Registered drug now withdrawn
Abiraterone (CB7630)–androgen synthesis inhibitor Phase I Phase I completed
Coumate–oestrone sulphatase inhibitor Phase I Phase I planning ongoing
Idoxifene–anti-oestrogen (tamoxifen analogue) Phase I/II Discontinued after Phase II Oestrogenic side effects
Rogletimide - oestrogen synthesis inhibitor Phase I Discontinued after Phase I Poor pharmacokinetics
Agents with novel or unknown mechanism of action
17-Allylaminogeldanamycin–HSP90 ATPase inhibitor Phase I Phase I study ongoing
Batimastat (BB94)–matrix metalloproteinase inhibitor Phase I Discontinued Superseded by improved
analogue marimastat
Boronphenylalanine–BNCT
1 reagent Phase I Phase I planning ongoing
Bryostatin 1–protein kinase C modulator Phase I/II Phase II studies ongoing
CB1954 with NQO2 substrate–bioreductive alkylator Phase I Phase I planning ongoing
Combretastatin-A4 phosphate–antivascular agent Phase I Phase II studies ongoing
CT2584–signal transduction inhibitor Phase I Discontinued after Phase II Problems with formulation
CYC202–cyclin-dependent kinase inhibitor Phase I Phase II studies planned
Decitabine–DNA methyltransferase inhibitor Phase I Phase I study ongoing
DMXAA–antivascular agent/cytokine modulator Phase I Phase II planning ongoing
Elactocin–unknown mechanism Phase I Discontinued after Phase I Unacceptable toxicity
FAA–antivascular agent/cytokine modulator Phase I Discontinued after Phase II Superseded by improved
analogue DMXAA
GR63178A–unknown mechanism Phase II Discontinued after Phase II Lack of activity
LM985–antivascular agent/cytokine modulator Phase I Discontinued after Phase I Superseded by improved
analogue FAA
LY195448–unknown mechanism Phase I Discontinued during Phase I Preclinical activity not confirmed
OSI774–EGF receptor kinase inhibitor Phase II Phase II planning ongoing
Patrin-2–O
6-alkylguanine alkyltransferase inactivator Phase I Phase II planning ongoing
Penclomidine–unknown mechanism Phase I Discontinued after Phase I Unacceptable toxicity
Phortress–cytochrome P450-activated cytotoxin Phase I Phase I planning ongoing
Phyllanthoside–DNA and protein synthesis inhibitor Phase I Discontinued after Phase I Unacceptable toxicity
RSU-1069–reductively-activated radiopotentiator Phase I Discontinued after Phase I Unacceptable toxicity
SDZ 62-434–unknown mechanism Phase I Discontinued after Phase I Lack of compound supply
PSC-833–P-glycoprotein antagonist Phase I Discontinued after Phase III Lack of sufficient activity
SPAG–mitogenic neuropeptide antagonist Phase I Discontinued during Phase I Lack of potency/rapid clearance
SR4554–magnetic resonance hypoxia imaging agent Phase I Phase I study ongoing
SU6668–growth factor receptor kinase inhibitor Phase I (oral) Discontinued during Phase I Problems with capsule manufacture
Suramin–growth factor antagonist Phase I/II Phase I/II study ongoing
TBI-699–DNA repair inhibitor Phase I Phase I planning ongoing
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and multiple myeloma) and TCR idiotypes (T-cell lymphoma).
Vaccination methods include the use of proteins, plasmids,
viruses, dendritic cells and combinations of these approaches. The
Phase I/II Committee has had a particular interest in the evaluation
of vaccines to exploit idiotypes, and studies with both antibody
and plasmid vaccination approaches were undertaken (Hawkins
et al, 1997). For example, in an ongoing trial of a plasmid vaccine
for the treatment of patients with B-cell lymphoma, the gene for
fragment C of tetanus toxin is fused with the lymphoma idiotype
gene from individual tumours and the fusion gene given as
repeated immunisations while the patient is in complete remission.
Doses of 0.5–2.5mg of plasmid DNA have been given and both
antitetanus and antiidiotype responses are being measured.
Looking to the future, viral DNA delivery, as opposed to naked
plasmid gene administration, may be more efficient (Armstrong
et al, 2002), either used alone or in combination with dendritic
cells. Recent studies with protein-loaded dendritic cells have
demonstrated clinical activity (Timmerman et al, 2002), and
dendritic cells have the advantage of efficient antigen uptake and
presentation, as well as the expression of the full range of accessory
molecules required for an efficient immunodynamic effect.
OVERVIEW AND CONCLUSIONS
This article has reviewed only selected aspects of the activities of
the Phase I/II Clinical Trials Committee since its creation in 1980,
and a full list of all the agents selected for clinical trials, as of
November 2002, is given in Table 2. Specific compounds have been
described in detail above, but in total 89 agents have been selected,
which includes 25 cytotoxic drugs, five antiendocrine agents, 28
molecules with novel or unknown mechanisms of action, five
polymeric antitumour drugs and 26 antibody-targeted agents/
immunotherapies. With these agents, no fewer than 85 Phase I and
17 Phase II trials have been performed or are planned by the Phase
I/II Committee. As appropriate for an academic clinical trials
group operating at the clinical-laboratory interface, activity has
deliberately been focused on hypothesis-testing clinical trials with,
increasingly, pharmacological or immunological end points.
Of the agents selected by the Phase I/II Committee, 23 are
currently undergoing Phase I evaluation (ie trials are either open
or planned), 36 did not progress beyond Phase I, and 30 proceeded
to further clinical investigation. For those which did not progress
beyond Phase I trials, the most common reason was unacceptable
toxicity. However, it is important to stress that in no case was
toxicity unacceptable at the Phase I trial starting dose and the
experience of the Committee, with a wide range of agents, is that
rodent-only toxicology does provide a safe Phase I trial starting
dose (Newell et al, 1999). The second most frequent reason for
compounds not progressing beyond Phase I trials is that the agent
was superseded by an improved analogue or derivative. Thus,
while the agent itself did not progress to become a therapeutic, the
Phase I trial performed by the Committee was nevertheless an
important contribution to cancer drug development. Other reasons
for compounds not progressing beyond Phase I trials included
Polymer targeted agents
Biotransdox–polymeric doxorubicin formulation Phase I Phase II studies ongoing
CT2103 (Xyotax)–polymeric paclitaxel Phase I/II Phase III studies ongoing
MAG-CPT–polymeric camptothecin Phase I Discontinued after Phase I Unacceptable toxicity
PK1–polymeric doxorubicin Phase I/II Phase II studies completed
PK2–galactose receptor targeted polymeric doxorubicin Phase I/II Phase II study planned
Antibody targeted agents and immunotherapies
105AD7–anti-idiotype CD55 vaccine Phase I/II Phase II study ongoing
5T4–epithelial tumour antigen vaccine Phase I Phase II studies ongoing
131I-AFP161–alphafoetoprotein imaging agent Phase I Discontinued after Phase I Adequate imaging not achieved
131I-A5B7–anti-CEA radioimmunotherapy Phase I Phase I planning ongoing Combination study with CA4P
99Tc-A5B7 /
125I-A5B7 /
131I-A5B7–CEA imaging agent Phase I Discontinued after Phase I Superseded by MFE23
ADEPT
2–A5B7 f(ab)2-CPG2 with CMDA prodrug Phase I Discontinued after Phase I CMDA superseded by ZD2767P prodrug
ADEPT–A5B7 f(ab)2-CPG2 with ZD2767P prodrug Phase I Discontinued after Phase I Conjugate superseded by MFE23-CPG2
ADEPT–MFE23-CPG2 with ZD2767P prodrug Phase I Phase I study ongoing
Anti-lymphoma idiotype DNA vaccine Phase I Discontinued after Phase I Superseded by idiotype/tetanus (LIFTT) vaccine
Anti-lymphoma idiotype/tetanus DNA vaccine (LIFTT) Phase I Phase I study ongoing
BU12-saporin–anti-CD19 immunotoxin Phase I Phase I study ongoing
67Cu-C595–anti-MUC-1radioimmunotherapy Phase I Phase I study ongoing
Chimeric B72.3–anti-colorectal antigen antibody Phase I Discontinued after Phase I Unacceptable immunogenicity
131I-CHT25–anti-IL2 receptor radioimmunotherapy Phase I Phase I study ongoing
EBV–Epstein–Barr virus vaccine Phase I Phase I planning ongoing
ICR62–anti-EGF receptor antibody Phase I Discontinued after Phase I Lack of antibody supply
HPV16–L1 capsid protein vaccine Phase I Phase I study ongoing
IL2 gene therapy–immunostimulation for melanoma Phase I Discontinued after Phase I Problems with manufacture
MID/2/40/C–epithelial antigen imaging agent Phase I Discontinued during Phase I Problems with manufacture
123I-MFE23–CEA imaging agent Phase I Discontinued after Phase I Led to MFE23-CPG2 ADEPT
MVA.EBNA.1–Epstein–Barr virus vaccine Phase I Phase I planning ongoing
131I-NY.3D11–NCAM imaging agent Phase I Discontinued after Phase I Poor localisation
OKT10-saporin–anti-CD38 immunotoxin Phase I Phase I study ongoing
PK45s–polyclonal sheep anti-CEA antibody Phase I Discontinued after Phase I Superseded by A5B7
SWA11–SCLC imaging agent Phase I Discontinued after Phase I Poor localisation
TNF alpha vaccine Phase I Discontinued after Phase I Lack of immune response
Table 2 (Continued)
Compound and mechanism of action CR-UK studies
Current status of agent
(not all CR-UK trials) Reasons for discontinuation
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of the clinical material.
Of the 30 agents that have progressed to clinical evaluation
beyond a Phase I trial, 11 are currently undergoing or are
scheduled for Phase II studies. For the 19 compounds where Phase
II evaluation has been completed, five were shown to be inactive
(BBR3464, CB10-277, DACA, GR63178A and rhizoxin), three were
superseded by improved derivatives (batimastat, FAA and
mitozolomide), two had formulation/manufacture problems
(CT2584 and trimelamol), and one (idoxifene) had poor pharma-
codynamics. Eight of the agents that entered Phase II trials, either
under the auspices of the Phase I/II Committee or elsewhere, had
activity at a level that warranted later stage clinical trials. Of these
eight drugs, four subsequently became registered therapies (4-
hydroxyandrostenedione, biantrazole, etoposide phosphate and
temozolomide), and trials with three agents (CT2103, JM216,
nolatrexed) are ongoing.
By any standards, the activities of the Phase I/II Committee
constitute an impressive achievement in the arena of Phase I/II
clinical trials. Overall, the Committee has made a significant
contribution to international anticancer drug discovery and
development. That this achievement can be traced directly back
to the vision and drive of Tom Connors is without question, and all
the cancer patients who have benefited, as well as clinical and
laboratory scientists who have undertaken the trials, owe Tom an
outstanding debt.
As this report illustrates, the achievements of the Phase I/II
Committee are already a lasting memorial to Tom Connors. Cancer
Research UK and all those involved in developmental therapeutics
in the UK now have a duty to ensure that the network created by
Tom, Brian Fox and Laszlo Lajtha in 1980 moves forward to even
greater success, and in so doing allows patients to benefit directly
from the advances in cancer molecular biology that are unleashing
a new generation of treatments.
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